Anxiety Disorder, Depression
Conditions
Keywords
depression, microbiota-gut-brain axis, Lactobacillus Plantarum 299v, probiotic
Brief summary
The aim of the study is to determine the influence of supplementation of probiotic Lactobacillus Plantarum 299V vs. placebo of probiotic during antidepressant monotherapy with SSRI (Selective Serotonin Reuptake Inhibitor) in patients with major depression.
Detailed description
For period of 8 weeks patient will receive probiotic Lactobacillus Plantarum 299V or its placebo as a supplementation of regular depression treatment with SSRI (Escitalopram or Sertraline). Psychometric and biochemical parameters will be monitored and evaluated. At day one, after 3 weeks (day 21) and after 8 weeks (day 56) of the study psychometric parameters will be measured such as Hamilton Depression Rating Scale, PSS-10 Scale, SCL-90 scale. At day one and after 8 weeks (day 56) of the study cognitive functions will be measured using: CVLT- California Verbal Learning Test, RFFT Ruff Figural Fluency Test, Stroop Test, Connecting Points Test (A and B), Attention and Perceptivity Test. At day one and after 8 weeks (day 56) of the study biochemical parameters will be measured such as: morning cortisol, pro and anti-inflammatory cytokines, tryptophan and its kynurenic pathway metabolites concentrations.
Interventions
Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
DRUGCrystalline cellulose powder
Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
DRUGEscitalopram
5-20mg daily
DRUGSertraline
50-100mg daily
Sponsors
Medical University of Bialystok
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Unipolar depression, with at least one depressive episode, present episode since at least 2 weeks, with Hamilton Depression Scale scoring 18 and higher with BMI =18,9 - 29,9 kg/m2
Exclusion criteria
* Inflammatory diseases eg. rheumatoid diseases, inflammatory bowel diseases, autoimmunological diseases * Metabolic diseases e.g. diabetes type I,II, obesity (Body Mass Index)\>30 kg/m2 * Previously diagnosed other psychiatric diseases other than depression, psychoactive substances abuse, organic brain dysfunctions * Smokers * Patients after surgeries in last 3 months * Oncological patients * Patients during pregnancy or lactation * Drugs which might influence measured parameters (e.g. lithium, antibiotics, glucocorticosteroids, antipsychotic drugs) * Changes in routine blood biochemical parameters: morphology, electrolytes, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), creatinine, urea, C-reactive protein (CRP), thyroid-stimulating hormone (TSH).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of psychometric parameters - Change in Hamilton Depression Rating Scale from baseline at 3 weeks and 8 weeks of the study. | At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study |
| Evaluation of psychometric parameters - Change in Perceived Stress Scale (PSS-10) from baseline at 3 weeks and 8 weeks of the study. | At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study |
| Evaluation of psychometric parameters - Change in Symptom Checklist 90 Scale (SCL-90) from baseline at 3 weeks and 8 weeks of the study. | At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive functions evaluation - Connecting Points Test (A and B) | At day one, after 8 weeks (day 56) of the study | — |
| Cognitive functions evaluation - Attention and Perceptivity Test | At day one, after 8 weeks (day 56) of the study | — |
| Cognitive functions evaluation - California Verbal Learning Test (CVLT) | At day one, after 8 weeks (day 56) of the study | — |
| Biochemical analysis - cytokines measurements profile | At day one, after 8 weeks (day 56) of the study | — |
| Biochemical analysis - kynurenic pathway metabolites measurements profile | At day one, after 8 weeks (day 56) of the study | — |
| Biochemical analysis - morning cortisol level | At day one, after 8 weeks (day 56) of the study | Biochemical analysis will be based on pro-inflammatory and anti-inflammatory cytokines measurements, morning cortisol concentration, tryptophan and its kynurenic pathway metabolites measurements. |
| Cognitive functions evaluation - Ruff Figural Fluency Test (RFFT) | At day one, after 8 weeks (day 56) of the study | — |
| Cognitive functions evaluation - Stroop Test (A and B) | At day one, after 8 weeks (day 56) of the study | — |
Countries
Poland
Outcome results
None listed